Early prescriptions were heavily concentrated in the self-pay starter dose, and the trajectory of coverage expansion and longer-term adherence remains uncertain
Manufacturer copay cards and patient assistance programs exclude uninsured self-pay patients by design
however, of these options dulaglutide is the most effective
*Correspondence: Matae Ahn, [email protected] Chao, [email protected] These authors have contributed equally to this work This article was submitted to Parkinsons Disease and Aging-related Movement Disorders, a section of the journal Frontiers in Aging Neuroscience Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
They are not intended to represent clinical evidence in humans, and IGF-1 LR3 has not been approved by the FDA, EMA, or any other regulatory authority for any indication